Management of pneumonitis post-concurrent chemoradiation and immunotherapy in patients with advanced lung cancer: Case report and litterature review
Year: 2024
Type: article
Study design: Case Report
Abstract: Immune-related pneumonitis is a rare but serious complication in patients with non-small cell lung cancer (NSCLC) treated with durvalumab after concurrent chemoradiotherapy (CRT). We encountered a 61-year-old male with stage III non-small cell lung cancer (NSCLC) receiving concurrent chemoradiotherapy followed by durvalumab maintenance therapy. After 1 cycle of durvalumab treatment, he developed progressive dyspnea, dry cough, and low-grade fever. Chest CT scans revealed diffuse ground-glass opacities in both lungs, indicative of immune-related pneumonitis. Durvalumab was discontinued, and the patient was treated with high-dose corticosteroids and antibiotics. After one month, he fully recovered. Durvalumab was cautiously resumed under close monitoring without recurrence of pneumonitis. Conclusion: Early identification and management of immune-related pneumonitis are essential in NSCLC patients receiving durvalumab. Reintroducing durvalumab after recovery may be safe with vigilant monitoring.
Source: Tạp chí Nghiên cứu Y học
Authors: Nguyen Van Hung, Nguyen Nhat Tan, Pham Duy Manh, Tran Trung Bach, Trinh Le Huy
Institution: Hanoi Medical University Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4404830267